Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pembrolizumab biosimilar by Bio-Thera Solutions for Solid Tumor: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Solid Tumor. According to GlobalData,...
Pembrolizumab biosimilar by Biocad for Solid Tumor: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Biocad and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Pembrolizumab biosimilar by Biocad for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Biocad and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Pembrolizumab biosimilar by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Amgen and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Pembrolizumab biosimilar by Samsung Bioepis for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Non-Small Cell Lung Cancer. According...
Pembrolizumab biosimilar by Sandoz Group for Melanoma: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Sandoz Group and currently in Phase I for Melanoma. According to GlobalData, Phase...